Related Experiment Videos
Vascular complications of inflammatory bowel disease
Insights
Patients with inflammatory bowel disease (IBD) face a significant risk of thromboembolic complications, including deep vein thrombosis and pulmonary emboli. Thrombocytosis and elevated inflammatory markers were common, with a high mortality rate observed in affected individuals.
Area of Science:
- Gastroenterology
- Hematology
- Vascular Medicine
Background:
- Inflammatory bowel disease (IBD), encompassing chronic ulcerative colitis and Crohn's disease, affects a substantial patient population.
- Thromboembolic complications represent a serious, potentially life-threatening concern in patients with IBD.
- Understanding the incidence and characteristics of these complications is crucial for effective patient management.
Purpose of the Study:
- To investigate the incidence and nature of thromboembolic complications in patients diagnosed with chronic ulcerative colitis or Crohn's disease.
- To identify associated risk factors and laboratory findings in IBD patients experiencing thromboembolic events.
- To explore the patterns of occurrence, differentiating between spontaneous and postsurgical events.
Main Methods:
- Retrospective analysis of 7,199 patients diagnosed with IBD between January 1970 and December 1980.
- Documentation of thromboembolic events, including deep vein thrombosis, pulmonary emboli, and other vascular complications.
- Assessment of laboratory markers such as thrombocytosis, erythrocyte sedimentation rate, fibrinogen, and factor VIII levels.
Main Results:
- Thromboembolic complications occurred in 1.3% (92 patients) of the IBD cohort, with deep vein thromboses and pulmonary emboli being the most frequent (61 cases).
- A high mortality rate of 25% was observed among patients with thromboembolic complications.
- Elevated erythrocyte sedimentation rate (73%), thrombocytosis (60%), and commonly increased fibrinogen and factor VIII levels were noted. Peripheral venous thromboses were often spontaneous (77%), while arterial and other visceral thromboses were primarily postsurgical.
Conclusions:
- Patients with IBD exhibit a notable risk of developing thromboembolic complications, characterized by thrombocytosis and inflammatory markers.
- The high mortality associated with these complications underscores the need for vigilant monitoring and proactive management strategies.
- Further research into the role of anticoagulation and surgical intervention is warranted for managing hypercoagulability in IBD patients.
Abstract:
During an 11-year period from January 1970 to December 1980, 7,199 patients at our institution had chronic ulcerative colitis or Crohn's disease. Thromboembolic complications developed in 92 (1.3%) of these patients. An additional 4 patients had cutaneous vasculitis, and 17 had an arteritis-associated diagnosis. Of the thromboembolic complications, 61 were deep vein thromboses or pulmonary emboli. The mortality among patients with thromboembolic complications was high (25%). Sixty percent of the patients had a thrombocytosis unaffected by sulfasalazine or corticosteroid therapy. In 73% of the patients, the erythrocyte sedimentation rate was increased, and when measured, fibrinogen and factor VIII were commonly elevated. Peripheral arterial thrombosis, coronary thrombosis, and mesenteric and portal vein thrombosis were predominantly postsurgical complications, but 77% of peripheral venous thromboses occurred spontaneously. The role of anticoagulation and surgical intervention in the management of hypercoagulation in patients with inflammatory bowel disease is discussed.